KPIs & Operating Metrics(New)
Growth Metrics

Chemed (CHE) Cost of Revenue (2016 - 2026)

Chemed filings provide 18 years of Cost of Revenue readings, the most recent being $441.7 million for Q1 2026.

  • For the quarter ending Q1 2026, Cost of Revenue rose 2.61% year-over-year to $441.7 million, compared with a TTM value of $1.7 billion through Mar 2026, up 5.9%, and an annual FY2025 reading of $1.7 billion, up 8.23% over the prior year.
  • Cost of Revenue hit $441.7 million in Q1 2026 for Chemed, up from $414.2 million in the prior quarter.
  • The five-year high for Cost of Revenue was $441.7 million in Q1 2026, with the low at $336.6 million in Q1 2022.
  • Median Cost of Revenue over the past 5 years was $385.1 million (2024), compared with a mean of $385.9 million.
  • The sharpest move saw Cost of Revenue dropped 3.9% in 2022, then rose 13.26% in 2024.
  • Year by year, Cost of Revenue stood at $349.6 million in 2022, then rose by 2.51% to $358.3 million in 2023, then increased by 13.26% to $405.9 million in 2024, then grew by 2.04% to $414.2 million in 2025, then increased by 6.66% to $441.7 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $441.7 million, $414.2 million, and $428.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.